US20170143810A1 - Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof - Google Patents

Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof Download PDF

Info

Publication number
US20170143810A1
US20170143810A1 US15/126,990 US201515126990A US2017143810A1 US 20170143810 A1 US20170143810 A1 US 20170143810A1 US 201515126990 A US201515126990 A US 201515126990A US 2017143810 A1 US2017143810 A1 US 2017143810A1
Authority
US
United States
Prior art keywords
globo
cancer
amino acid
acid sequence
padre
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/126,990
Other languages
English (en)
Inventor
Chih-Long Chang
Chao-chih WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mackay Memorial Hospital
Original Assignee
Mackay Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mackay Memorial Hospital filed Critical Mackay Memorial Hospital
Priority to US15/126,990 priority Critical patent/US20170143810A1/en
Assigned to MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION reassignment MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, CHIH-LONG, WU, Chao-chih
Assigned to MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION, DCB-USA, LLC reassignment MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION
Assigned to MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL reassignment MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL, DCB-USA, LLC
Publication of US20170143810A1 publication Critical patent/US20170143810A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to the field of immunotherapy of cancer.
  • the disclosed invention relates to an immunogenic glycopeptide, a pharmaceutical composition comprising the glycopeptide and to the use thereof for enhancing the immune response and notably in cancer therapy.
  • Globo H (Fuc ⁇ 1 ⁇ 2Gal ⁇ 1 ⁇ 3GalNAc ⁇ 1 ⁇ 3Gal ⁇ 1 ⁇ 4Gal ⁇ 1 ⁇ 4Glc ⁇ 1 ⁇ O-cer) is a hexasaccharide and belongs to a large number of tumor-associated carbohydrate antigens that are overexpressed on the surface of various epithelial cancer cells, including breast, colon, ovarian, pancreatic, lung, and prostate cancer cells.
  • the aberrant expression of Globo H renders it an attractive candidate for immunotherapy and the development of cancer vaccines for Globo H-expressing cancers.
  • 20010048929 provided a multivalent immunogenic molecule, comprising a carrier molecule containing at least one functional T-cell epitope, and multiple different carbohydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope, wherein said carrier molecule imparts enhanced immunogenicity to said multiple carbohydrate fragments and wherein the carbohydrate fragment is Globo H, Le Y or STn.
  • 20120328646 provides a carbohydrate based vaccine containing Globo H (B cell epitope) chemically conjugated to the immunogenic carrier diphtheria toxin cross-reacting material 197 (DT-CRM 197) (Th epitope) via a p-nitrophenyl linker, which provides immunogenicity in breast cancer models, showing delayed tumorigenesis in xenograft studies.
  • Globo H B cell epitope
  • DT-CRM 197 Th epitope
  • 20120263749 relates to a polyvalent vaccine for treating cancer comprising at least two conjugated antigens selected from a group containing glycolipid antigen such as Globo H, a Lewis antigen and a ganglioside, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant.
  • the present disclosure is directed to an immunogenic glycopeptide or a derivative thereof, wherein the immunogenic glycopeptide or a derivative thereof may elicit high titers of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies against Globo H in vivo.
  • immunoglobulin G immunoglobulin G
  • IgM immunoglobulin M
  • the immunogenic glycopeptide has the structure of:
  • PADRE is a pan-DR epitope and has at least 10 consecutive amino acid residues that is at least 90% identical to the amino acid sequence of AKXVAAWTLKAAA (SEQ ID NO: 1), where X is a cyclohexylalanine residue; and wherein P is Globo H, GD2, GM2, SSEA 4, Lewis Y or STn.
  • amino acid sequence of the PADRE is identical to the amino acid sequence of SEQ ID NO: 1.
  • the present disclosure is directed to a pharmaceutical composition for treating a cancer in a subject in need thereof.
  • the pharmaceutical composition comprises, (1) a therapeutically effective amount of the immunogenic glycopeptide according to any of the above-mentioned aspect/embodiments of the present disclosure and (2) a pharmaceutically acceptable carrier.
  • the cancer is any of tumor-associated carbohydrate-expressing cancers; preferably, the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer or lung cancer.
  • the present disclosure is directed to a method of treating a tumor-associated carbohydrate-expressing cancer in a subject in need thereof.
  • the method includes administering to the subject the immunogenic glycopeptide or pharmaceutical composition according to any of the aspects/embodiments described in the present disclosure.
  • FIGS. 1 (A) and (B) provide bar graphs illustrating the IgM titers of mice immunized with the Globo H-PADRE glycopeptide according to one working example of the present disclosure ( FIG. 1(A) for diluted serum IgM 1:100 and FIG. 1(B) for diluted serum IgM 1:1000).
  • FIGS. 2 (A) and (B) provide bar graphs illustrating the IgG titers of mice immunized with the Globo H-PADRE glycopeptide according to one working example of the present disclosure ( FIG. 2(A) for diluted serum IgG 1:100 and FIG. 2(B) for diluted serum IgG 1:1000).
  • FIGS. 3 (A) and (B) show the binding affinity of the anti-Globo H IgG and IgM antibodies with Globo H ( FIG. 3(A) for binding affinity of anti-Globo H IgG antibodies with Globo H and FIG. 3(B) for binding affinity of anti-Globo H IgM antibodies with Globo H).
  • FIGS. 4 (A) and (B) show that mMouse immunized with 2 ⁇ g of glycopeptide by direct conjugation of PADRE to Globo and QS 21 adjuvant (2 ⁇ g) exhibits high-titer of anti-Globo H IgG and IgM with immune boost effect.
  • MZ-11-Globo H Globo H-PADRE
  • MZ-11-4KA-Globo H PADRE-branched Globo H.
  • FIG. 5 shows that antibodies in serum from mice vaccinated with Globo H-PADRE (+adjuvant QS21) bind to Globo H-expressing MCF-7 cells.
  • FIGS. 6 (A) and (B) show that glycopeptide Globo H-PADRE (M) induces higher titer of anti-Globo H IgG antibody than general carrier protein-Globo H conjugation (C) does.
  • C control;
  • Q adjuvant QS21.
  • FIG. 6(A) refers to the results of mouse-anti-Globo IgG ELISA and
  • FIG. 6(B) refers to the results of mouse-anti-Globo IgM ELISA.
  • FIGS. 7(A) and 7(B) shows that antibody titers in individual mouse receiving glycopeptide Globo H-PADRE are constantly high, whereas antibody titers in mouse receiving carrier protein-Globo H conjugation are variable and most are low.
  • FIG. 7(A) refers to the results of G vaccine Mouse anti-GloboH IgG ELISA and FIG. 7(B) refers to the results of MZ-11-Globo vaccine Mouse anti-Globo IgG ELISA.
  • G1-G10 represent mouse No.1-No.10 receiving carrier protein-Globo H vaccine.
  • M1-M10 represent mouse No.1-N.10 receiving glycopeptide Globo H-PADRE vaccine.
  • FIGS. 8 (A) and (B) show that glycopeptide Globo H-PADRE (M) induces long-term anti-Globo H IgG, whereas general carrier protein-Globo H conjugation (G) does not.
  • FIG. 8(A) refers to the results of mouse serum anti-GloboH IgG and
  • FIG. 8(B) refers to the results of mouse serum anti-GloboH IgM.
  • FIGS. 9(A) and (B) show that dissection of individual mouse receiving glycopeptide Globo H-PADRE shows constantly long-lived high-titer anti-Globo H IgG antibody ( FIG. 9(A) for D 109 mouse serum anti-GliboH IgG and FIG. 9(B) for D109 mouse serum anti-GliboH IgM).
  • G1-G10 represent mouse No.1-No.10 receiving carrier protein-Globo H vaccine.
  • Ml-M10 represent mouse No.1-N.10 receiving glycopeptide Globo H-PADRE vaccine.
  • FIGS. 10(A) and (B) show that GM 2 -PADRE glycopeptide induces high-titer anti-carbohydrate IgG antibody ( FIG. 10(A) for the induction of IgG and FIG. 10(B) for the induction of IgM).
  • FIG. 11 shows that mouse treated by Globo H-PADRE vaccine demonstrated slower tumor growth.
  • FIG. 12 shows that mouse treated by adoptive transfer of serum from mice immunized by Globo H-PADRE vaccine showed small tumor burden.
  • FIGS. 13(A) to (H) shows polyvalent vaccines composed of Globo H-, GM2-, Lewis Y-PADRE conjugation mixtures or SSEA4, GM2, Lewis Y-PADRE conjugation mixtures can induce high-titer of IgG against each of respective carbohydrate antigen ( FIG. 13(A) for Globo IgG; FIG. 13(B) for Globo IgM; FIG. 13(C) for GM 2IgG; FIG. 13(D) for GM2 IgM; FIG. 13 (E) for LewisY IgG; FIG. 13(F) for LewisY IgM; FIG. 13(G) for SSEA4 IgG and FIG. 13(H) for SSEA4 IgM).
  • the present invention is based, at least, on the finding that the glycopeptide conjugate of a tumor-associated carbohydrate antigen and the PADRE sequence is capable of eliciting an immune response in a mammal.
  • the glycopeptide facilitates the activation of both B cells and T cells, thereby resulting in the production of IgM and IgG that specifically bind to the carbohydrate antigen.
  • the glycopeptide conjugate can be used as a vaccine capable of inducing high-titer anti-carbohydrate IgG antibody for treating cancer expression tumor-associated carbohydrate antigens.
  • polyvalent glycopeptide conjugate vaccine elicites high-titer polyvalent anti-carbohydrate IgG antibodies for treating cancer expressing tumor-associated carbohydrate antigens.
  • the present disclosure is directed to an immunogenic glycopeptide.
  • the immunogenic glycopeptide according to the present disclosure can be provided for use in treating (including preventing) cancer; for example, it shall be manufactured as a medicament, e.g., comprised in a pharmaceutical composition.
  • the present immunogenic glycopeptide and the pharmaceutical composition comprising the same can also be applied in a method for treating and/or preventing cancer.
  • the present disclosure also contemplates a method for treating cancer in a subject suffering therefrom comprising administering to said subject a therapeutically effective amount of the glycopeptide or pharmaceutical composition as defined herein.
  • antigen as used herein is defined as a substance capable of eliciting an immune response. Said immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
  • immunogen refers to an antigen capable of inducing the production of an antibody.
  • immunoogenicity generally refers to the ability of an immunogen or antigen to stimulate an immune response.
  • epitope refers to a unit of structure conventionally bound by an immunoglobulin V H /V L pair.
  • An epitope defines the minimum binding site for an antibody, and thus represent the target of specificity of an antibody.
  • glycopeptide refers to a compound in which carbohydrate is covalently attached to a peptide or oligopeptide.
  • the left-hand direction is the amino-terminal (N-terminal) direction and the right-hand direction is the carboxy-terminal (C-terminal) direction, in accordance with standard usage and convention.
  • Percentage (%) amino acid sequence identity with respect to the amino acid sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • sequence comparison between two amino acid sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by National Center for Biotechnology Information (NCBI).
  • Blastp protein-protein BLAST
  • NCBI National Center for Biotechnology Information
  • X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program's alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.
  • amino acid sequences of proteins/polypeptides are contemplated as being encompassed by the presently disclosed and claimed inventive concept(s), providing that the variations in the amino acid sequence maintain at least 90%, such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99%.
  • conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains.
  • More preferred families are: serine and threonine are aliphatic-hydroxy family; asparagine and glutamine are an amide-containing family; alanine, valine, leucine and isoleucine are an aliphatic family; and phenylalanine, tryptophan, and tyrosine are an aromatic family.
  • serine and threonine are aliphatic-hydroxy family
  • asparagine and glutamine are an amide-containing family
  • alanine, valine, leucine and isoleucine are an aliphatic family
  • phenylalanine, tryptophan, and tyrosine are an aromatic family.
  • Whether an amino acid change results in a functional peptide can readily be determined by assaying the specific activity of the polypeptide derivative. Fragments or analogs of proteins/polypeptides can be readily prepared by those of ordinary skill in the art. Preferred amino-and carboxy-termini of fragments or analogs occur near boundaries of functional domains.
  • treatment are used herein broadly to include a preventative (e.g., prophylactic), curative, or palliative measure that results in a desired pharmaceutical and/or physiological effect.
  • a preventative e.g., prophylactic
  • curative e.g., palliative
  • palliative measure that results in a desired pharmaceutical and/or physiological effect.
  • the effect is therapeutic in terms of partially or completely curing or preventing cancer.
  • treatment refers to application or administration of the present immunogenic glycopeptide, antibody, or pharmaceutical composition comprising any of the above to a subject, who has cancer, a symptom of cancer, a disease or disorder secondary to cancer, or a predisposition toward cancer, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of cancer.
  • a “treatment” includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment.
  • the term “treating” can also be used herein in a narrower sense which refers only to curative or palliative measures intended to ameliorate and/or cure an already present disease state or condition in a patient or subject.
  • preventing refers to a preventative or prophylactic measure that stops a disease state or condition from occurring in a patient or subject. Prevention can also include reducing the likelihood of a disease state or condition from occurring in a patient or subject and impeding or arresting the onset of said disease state or condition.
  • therapeutically effective amount refers to the quantity of an active component which is sufficient to yield a desired therapeutic response.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the compound or composition are outweighed by the therapeutically beneficial effects.
  • a “pharmaceutically acceptable carrier” is one that is suitable for use with the subjects without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
  • each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition.
  • the carrier can be in the form of a solid, semi-solid, or liquid diluent, cream or a capsule.
  • the carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, and is selected to minimize any degradation of the active agent and to minimize any adverse side effects in the subject.
  • adjuvant refers to an immunological agent that modifies the effect of an immunogen, while having few if any direct effects when administered by itself It is often included in vaccines to enhance the recipient's immune response to a supplied antigen, while keeping the injected foreign material to a minimum. Adjuvants are added to vaccines to stimulate the immune system's response to the target antigen, but do not in themselves confer immunity.
  • the term “subject” refers to a mammal including the human species that is treatable with antibody.
  • the term “subject” is intended to refer to both the male and female gender unless one gender is specifically indicated.
  • the present invention provides an immunogenic glycopeptide having the following structure:
  • the PADRE is a pan-DR epitope and has at least 10 consecutive amino acid residues that is at least 80% identical to the amino acid sequence of AKXVAAWTLKAAA (SEQ ID No. 1 ), where X is a cyclohexylalanine residue; and wherein P is Globo H, GD2, GM2, SSEA 4, Lewis, LewisY or STn.
  • the sequence identity as mentioned above is at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
  • the PADRE sequence is a non-natural sequence engineered to introduce anchor residues for different known DR-binding motifs.
  • X (cyclohexylalanine) in position 3 is an aliphatic residue corresponding to the position 1 of DR-binding motif
  • T in position 8 is a non-charged hydroxylated residue corresponding to position 6 of DR-binding
  • a in position 11 is a small hydrophobic residue corresponding to position 9 of the DR-binding motif
  • substituting one residue with another residue of substantially the same chemical and/or structural property e.g., substituting X (cyclohexylalanine) with aromatic F (phenylalanine)
  • aromatic F phenylalanine
  • amino acid sequence of the PADRE is identical to the amino acid sequence of SEQ ID No. 1.
  • the PADRE sequence has 10 to 20 amino acid residues.
  • the last residue (K) can be omitted.
  • the first residue (A) or the first two residues (A and K) are omitted.
  • the PADRE sequence is lack of the first two residues and the last residue.
  • the present immunogenic glycopeptide or a pharmaceutical composition comprising the same is administered to the subject in a therapeutically (or immunogenically) effective amount. Accordingly, the pharmaceutical composition and treating method also fall within the scope of the present invention.
  • the invention provides a pharmaceuticala composition comprising one or more immunogenic glycopeptide of the present invention as described herein.
  • the composition is a vaccine.
  • the composition is a vaccine.
  • the composition is a polyvalent vaccine comprising one or more Globo H- , GM2-, Lewis Y, or SSEA4-PADRE glycopeptide as described herein.
  • the composition is a polyvalent vaccine comprises Globo H- , GM2- and Lewis Y-PADRE glycopeptides or SSEA4- , GM2 and Lewis Y-PADRE glycopeptides, as described herein.
  • said pharmaceutical composition can further comprises a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may further comprises one or more pharmaceutically acceptable additives, including binders, flavorings, buffering agents, thickening agents, coloring agents, anti-oxidants, diluents, stabilizers, buffers, emulsifiers, dispersing agents, suspending agents, antiseptics and the like.
  • said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may further comprises one or more pharmaceutically acceptable additives, including binders, flavorings, buffering agents, thickening agents, coloring agents, anti-oxidants, diluents, stabilizers, buffers, emulsifiers, dispersing agents, suspending agents, antiseptics and the like.
  • compositions of the present invention may be administered orally or subcutaneous, intravenous, intrathecal or intramuscular injection.
  • Injectables for administration can be prepared in sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Common parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils; whereas intravenous vehicles often include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
  • the pharmaceutically acceptable carrier may be an immunogenic adjuvant.
  • the present pharmaceutical composition may optionally comprise an immunogenic adjuvant.
  • An immunogenic adjuvant is a compound that, when combined with an antigen, increases the immune response to the antigen as compared to the response induced by the antigen alone.
  • an adjuvant may augment humoral immune responses, cell-mediated immune responses, or both.
  • immunogenic adjuvants include, but are not limited to mineral salts, polynucleotides, polyarginines, ISCOMs, saponins, monophosphoryl lipid A, imiquimod, CCR-5 inhibitors, toxins, polyphosphazenes, cytokines, immunoregulatory proteins, immunostimulatory fusion proteins, co-stimulatory molecules, and combinations thereof.
  • Mineral salts include, but are not limited to, AIK(SO 4 ) 2 , AINa(SO 4 ) 2 , AlNH(SO 4 ) 2 , silica, alum, Al(OH) 3 , Ca 3 (PO4) 2 , kaolin, or carbon.
  • Useful immunostimulatory polynucleotides include, but are not limited to, CpG oligonucleotides with or without immune stimulating complexes (ISCOMs), CpG oligonucleotides with or without polyarginine, poly IC or poly AU acids.
  • Toxins include cholera toxin.
  • Saponins include, but are not limited to, QS21, QS17 or QS7.
  • examples of are muramyl dipeptides, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-DMP), N-acetyl-nornuramyl-L-alanyl-D-isoglutamine, N-acetylmuramyul-L-alanyl-D-isoglutaminyl-L-alanine-2-(1 '2'-dipalmitoyl-sn-glycero-3-hydroxphosphoryloxy)-ethylamine RIBI (MPL+TDM+CWS) in a 2 percent squalene/TWEEN 80 emulsion, lipopolysaccharides and its various derivatives, including lipid A, Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvants, Merck Adjuvant 65, polynucleotides (e.g.
  • poly IC and poly AU acids wax D from Mycobacterium tuberculosis, substances found in Corynebacterium parvum, Bordetella pertussis, and members of the genus Brucella, Titermax, Quil A, ALUN, Lipid A derivatives, choleratoxin derivatives, HSP derivatives, LPS derivatives, synthetic peptide matrixes or GMDP, Montanide ISA-51 and QS-21, CpG oligonucleotide, poly I:C, and GMCSF. Combinations of adjuvants can also be used.
  • the adjuvant is aluminum salts (such as aluminum phosphate and aluminum hydroxide), calcium phosphate, polyinosinic-polycytidylic acid (poly I:C), CpG motif, and saponins (such as Quil A or QS21).
  • the adjuvant is aluminum hydroxide or QS21.
  • the present invention provides a method for preventing and/or treating a cancer, comprises administering an effective amount of the immunogenic glycopeptide described herein or a derivative thereof to a subject.
  • the therapeutically effective amount of the immunogenic glycopeptide for mice could be expressed as 0.08-27 mg/kg body weight.
  • the therapeutically Effective amount for a human subject can be estimated from the animal doses according to various well-established standards or conversion means.
  • the “Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers” by Food and Drug Administration of U.S. Department of Health and Human Services provides several conversion factors for converting animal doses to human equivalent doses (HEDs).
  • HEDs human equivalent doses
  • mice weighted between 11 to 34 grams to convert the mice dose (in mg/kg) to HED (in mg/kg) for a 60 kg adult human, the mice dose is multiplied by 0.081.
  • the therapeutically effective amount of the present immunogenic glycopeptide for an adult human subject is 0.06-2.2 mg/kg body weight.
  • the therapeutically effective amount of the immunogenic glycopeptide can be at least 1 mg/kg.
  • the cancer treatable by the immunogenic glycopeptide, the pharmaceutical composition comprising the same or the treating method described herein is tumor-associated carbohydrate-expressing cancers; preferably, the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer or lung cancer.
  • PADRE-azide 5.5 mg was dissolved in 110 ⁇ l of DMSO, and 5 mg of Globo H-b-N-acetyl propargyl (Carbosynth) was dissolved in 1 ml of distilled water, wherein PADRE has the sequence as shown in SEQ ID NO: 1 .
  • Serum from na ⁇ ve mice injected with PBS and serum from mice immunized with the adjuvant only were used as negative controls.
  • Sera raised against the MBr1 antibodies (Enzo Life Science; 0.5 ⁇ g/ml) or MZ-2 antibodies (produced in Example 3 below; 1 ⁇ g/ml) were used as positive controls.
  • diluted serum (1:100 or 1:1000) from mice immunized with Globo H-PADRE was added into designated wells of a 96-well ELISA plate and incubated at room temperature for one hour. Wells were then washed six times with 0.1% Tween-20 in 1XPBS. Thereafter, 1:2500 diluted anti-mouse IgG-HRP or anti-mouse IgM-HRP (Jackson Immuno Research) was added to the wells and incubated at room temperature for another one hour, and washed six times with 0.1% Tween-20 in 1XPBS. Color development was performed by incubation of the washed wells with DMT ELISA kit, and stopped by adding 2N H 2 SO 4 .
  • FIG. 1 FIG. (A) for diluted serum IgM 1:100 and FIG. (B) for diluted serum igM 1:1000
  • FIG. 2 FIG. (A) for diluted serum IgG 1:100 and FIG. (B) for diluted serum IgG 1:1000).
  • the data in FIG. 1 indicate that Globo H-PADRE glycopeptide induced the production of anti-Globo H IgM.
  • the anti-Globo H IgM titers increased as immunization proceeded.
  • a cell binding assay was performed to elucidate the binding affinity of the anti-Globo H IgG and IgM antibodies with Globo H. Briefly, 100 ⁇ l of 1:10 diluted serum or 10 ⁇ g/ml of monoclonal antibodies in 1 ⁇ PBS were incubated with 2 ⁇ 10 5 of cells at room temperature for 20 minutes. The cells were washed once with 2 ml of 1 ⁇ PBS. After centrifugation, the wash buffer was discarded and cells were resuspended in 100 ⁇ l of 1:100 diluted PE anti-mouse IgG-Fc (Jackson immunoresearch) or 100 ⁇ l of 1:100 diluted PE anti-mouse IgM (eBioscience) and incubated again at room temperature for 20 minutes.
  • FIG. 3 results of cell binding assay are summarized in FIG. 3 ( FIG. 3(A) for binding affinity of anti-Globo H IgG antibodies with Globo H and FIG. 3(B) for binding affinity of anti-Globo H IgM antibodies with Globo H).
  • FIG. 3 anti-Globo H IgG antibodies obtained from immunizations with the present Globo H-PADRE glycopeptide displayed excellent recognition of MCF-7 cells which express the Globo H antigen.
  • mice were immunized 3 times with 2 ug or 8 ug of single Globo H conjugated vaccine (MZ- 11 -Globo H) or 8 ug of 4 Globo H conjugated vaccine (MZ-11-4KA-Globo H) plus QS-21 as adjuvant at a 2-week interval. Serum was harvested before and 7 days after each immunization.
  • streptavidin 21135, Thermo
  • 1 ug of streptavidin was dissolved in 100 uL of 1 ⁇ PBS and coated on 96-well Costar assay plate (9018, Coming) before loading of biotin-Globo H (0.1 ug/well).
  • FIG. 4 shows that mMouse immunized with 2 ⁇ g of glycopeptide by direct conjugation of PADRE to Globo and QS 21 adjuvant (2 ⁇ g) exhibits high-titer of anti-Globo H IgG and IgM with immune boost effect.
  • MZ- 11 -Globo H Globo H-PADRE
  • MZ-11-4KA-Globo H PADRE-branched Globo H.
  • mice were immunized 3 times with adjuvant alone or 2, 6, or 18 ug of Globo H-PADRE (MZ-11-Globo H) at a 2-week interval. Anti-serum were harvested 7 days after last immunization. Serum from mice without immunization was collected as control.
  • FACS 5 ⁇ 10 5 of MCF-7 cells were stained with 100 uL of 1:10 diluted serum in flow tube followed by 100 uL of 1:100 diluted PE-conjugated goat anti-mouse IgG-Fc antibody (115-116-071, Jackson immunoresearch) and 1:100 diluted APC-conjugated rat anti-mouse IgM (17-5790-82, eBioscience).
  • FIG. 5 shows that antibodies in serum from mice vaccinated with Globo H-PADRE (+adjuvant QS21) bind to Globo H-expressing MCF-7 cells.
  • C57BL/6 mice were immunized with adjuvant (QS 21 20 ug/mice), 2 ug of general carrier protein-Globo H conjugation (G) vaccine, or Globo H-PADRE conjugation (MZ11-GloboH) vaccine at a 2-week interval.
  • Anti-Globo H serum was harvested before and 7 days after each vaccination.
  • the titer of anti-Globo H serum in pooled serum or each mice were detected by ELISA assay with appropriated secondary antibody.
  • FIG. 6 shows that glycopeptide Globo H-PADRE (M) induces higher titer of anti-Globo H IgG antibody than general carrier protein-Globo H conjugation (C) does.
  • FIG. 7 shows that antibody titers in individual mouse receiving glycopeptide Globo H-PADRE are constantly high, whereas antibody titers in mouse receiving carrier protein-Globo H conjugation are variable and most are low and it represents that Globo H-PADRE (M) stably induces high titer of anti-Globo H IgG in individual mouse.
  • M Globo H-PADRE
  • Anti-Globo H serum was harvested on 36 and 81 days after last Vaccination (D64 and D109).
  • the titer of anti-Globo H antibodies The titers of anti-Globo H serum in pooled serum or each mouse were detected by ELISA assay with appropriated secondary antibody with 1/10000 dilution.
  • FIG. 8 shows that glycopeptide Globo H-PADRE (M) induces long-term anti-Globo H IgG, whereas general carrier protein-Globo H conjugation (G) does not and
  • FIG. 9 shows that dissection of individual mouse receiving glycopeptide Globo H-PADRE shows constantly long-lived high-titer anti-Globo H IgG antibody. Very low level of anti-Globo H IgG antibody is noted in mouse receiving carrier protein-Globo H conjugation.
  • C57BL/6 mice were immunized with adjuvant (QS21 20 ug/mice) or GM2-PADRE conjugation vaccine with adjuvant (QS-21 20 ug/mice) at a 2-week interval.
  • Anti-GM2 serum was harvested before and 7 days after each vaccination. The titer of anti-GM2 serum in pooled serum or each mice were detected by ELISA assay with appropriated secondary antibody.
  • FIG. 10 shows that GM 2 -PADRE glycopeptide induces high-titer anti-carbohydrate IgG antibody.
  • mice were divided into 3 groups and subcutaneously (s.c.) administered with 1 ⁇ PBS (control), 20 ug of QS-21 alone or 6 ug of Globo H-PADRE (MZ11-Globo H) plus 20 ug of QS-21 at a 2-week interval. Seven days after third vaccination, mice were s.c. implanted 1 ⁇ 10 5 of LLC1 cells and were concomitantly vaccinated again. The vaccination interval was changed to 7 days after tumor inoculation. Tumor size was measured by caliper at day 7, 10, 14 and 18 after tumor implantation and calculated at length ⁇ width ⁇ height.
  • FIG. 11 shows that mouse treated by Globo H-PADRE vaccine demonstrated slower tumor growth (LLC1 cells subcutaneous tumor model in immuno-competent mice).
  • mice were divided into 2 groups. Serum was collected from group 1 mice without immunization as control. Serum was also collected from group 2 mice vaccinated with Globo H-PADRE (MZ11-Globo H) 3 times at a 2-week interval as anti-Globo H serum.
  • One million TOV21G cells were intra-peritoneal (i.p.) implanted into 5-week-old female NU/NU mice (BioLASCO Taiwan). After 4 days, mice were administered with 200 ⁇ L of control serum or anti-GloboH serum 3 times a week through i.p. route. Untreated mice were set as control. For monitoring tumor growth, tumor bearing mice were i.p. injected 2004 of luciferin (3.9 mg/ml). The chemoluminescent intensity of each mouse was detected by a non-invasive IVIS system (Xenogen) with fixed exposure condition per batch of experiment.
  • Xenogen non-invasive IVIS system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/126,990 2014-03-19 2015-03-19 Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof Abandoned US20170143810A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/126,990 US20170143810A1 (en) 2014-03-19 2015-03-19 Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955216P 2014-03-19 2014-03-19
PCT/US2015/021421 WO2015143126A1 (fr) 2014-03-19 2015-03-19 Glycopeptides immunogènes, composition comprenant les glycopeptides et leur utilisation
US15/126,990 US20170143810A1 (en) 2014-03-19 2015-03-19 Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof

Publications (1)

Publication Number Publication Date
US20170143810A1 true US20170143810A1 (en) 2017-05-25

Family

ID=54145306

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/126,990 Abandoned US20170143810A1 (en) 2014-03-19 2015-03-19 Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
US15/126,945 Active US9828436B2 (en) 2014-03-19 2015-03-19 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
US15/655,105 Expired - Fee Related US9951143B2 (en) 2014-03-19 2017-07-20 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
US15/922,810 Abandoned US20180371103A1 (en) 2014-03-19 2018-03-15 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/126,945 Active US9828436B2 (en) 2014-03-19 2015-03-19 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
US15/655,105 Expired - Fee Related US9951143B2 (en) 2014-03-19 2017-07-20 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
US15/922,810 Abandoned US20180371103A1 (en) 2014-03-19 2018-03-15 Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof

Country Status (11)

Country Link
US (4) US20170143810A1 (fr)
EP (2) EP3119424A4 (fr)
JP (1) JP2017518958A (fr)
KR (1) KR20170003912A (fr)
CN (2) CN106456766B (fr)
AU (1) AU2015231256A1 (fr)
CA (2) CA2943333A1 (fr)
IL (1) IL247659A0 (fr)
MX (1) MX2016012124A (fr)
TW (2) TW201622743A (fr)
WO (2) WO2015143123A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3028048B1 (fr) 2013-07-31 2018-09-26 BioVentures, LLC Compositions permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur
EP3046588B1 (fr) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions de vaccin à base de glucides permettant d'induire des réponses immunitaires et utilisations associées dans le traitement du cancer
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
ES2772817T3 (es) * 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
EP3344806A4 (fr) 2015-09-04 2019-03-20 OBI Pharma, Inc. Réseaux de glycanes et leur procédé d'utilisation
WO2017048823A1 (fr) * 2015-09-18 2017-03-23 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Composés glycopeptides immunogènes, compositions pharmaceutiques et leurs utilisations
AU2016335842A1 (en) * 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) * 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
TW201825522A (zh) * 2016-09-23 2018-07-16 張志隆 抗-globo h 抗體
WO2018094414A1 (fr) 2016-11-21 2018-05-24 Obi Pharma, Inc. Molécules biologiques conjuguées, compositions pharmaceutiques et procédés
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
EP3638306A4 (fr) * 2017-06-15 2020-07-01 Development Center for Biotechnology Conjugués anticorps-médicament contenant des anticorps anti-globo h et leurs utilisations
US20180371089A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
CN112312924A (zh) * 2018-06-01 2021-02-02 台湾浩鼎生技股份有限公司 通过使用抗Globo H或抗SSEA-4抗体与抗负面免疫检查点抗体的联合疗法
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
EP3852779A4 (fr) * 2018-09-17 2022-06-08 Abcuro, Inc. Anticorps anti-klrg1
EP3799881A1 (fr) * 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Anticorps à domaine unique se liant spécifiquement aux glycanes de la série globo
CN110665001A (zh) * 2019-11-14 2020-01-10 上海农林职业技术学院 一种水性复合佐剂、其应用及猫用疫苗
KR102506295B1 (ko) * 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
CN112675298B (zh) * 2020-12-28 2024-05-03 中国医学科学院医学生物学研究所 一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用
CN118949024B (zh) * 2024-08-05 2025-06-10 成都迈科康生物科技有限公司 免疫调节剂在制备动物癌症治疗的组合物中的应用
WO2026052782A1 (fr) 2024-09-06 2026-03-12 Tacalyx Gmbh Anticorps anti-globo h

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049197A1 (en) 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US6544952B1 (en) 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
AU1582797A (en) * 1996-01-24 1997-08-20 Epimmune, Inc. Induction of immune response against desired determinants
US6676946B2 (en) 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070178095A1 (en) * 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
JP4702950B2 (ja) * 2005-03-28 2011-06-15 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置、ならびに、電子写真感光体の製造方法
US20070202578A1 (en) 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009137677A2 (fr) 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Réactifs, procédés et systèmes de détection de staphylocoques résistants à la méthicilline (sarm)
JP2011524375A (ja) * 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
WO2010006343A2 (fr) 2008-07-11 2010-01-14 Sloan-Kettering Institute For Cancer Research Constructions glycopeptidiques, et leurs utilisations
WO2010127180A2 (fr) * 2009-04-30 2010-11-04 University Of Rochester Anticorps anti-dc-stamp
CN102215862B (zh) * 2009-06-16 2016-04-06 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
TW201118166A (en) * 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011115483A1 (fr) * 2010-03-15 2011-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptides, conjugués et procédé permettant d'augmenter l'immunogénicité d'un vaccin
WO2011123857A1 (fr) * 2010-04-02 2011-10-06 Kalobios Pharmaceuticals, Inc. Génération d'anticorps d'un épitope d'intérêt
KR101764453B1 (ko) * 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
CA2801922A1 (fr) 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Constructions glycopeptidiques multivalentes et leurs utilisations
WO2011156751A2 (fr) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Vaccin immunogéne
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
CA2897084C (fr) 2013-01-04 2019-07-16 Cheng Der Tony Yu Vaccins a forte densite en antigenes carbohydrates et comportant un adjuvant inedit a base de saponine
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EP3046588B1 (fr) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions de vaccin à base de glucides permettant d'induire des réponses immunitaires et utilisations associées dans le traitement du cancer
EP3054974A4 (fr) 2013-10-10 2017-06-14 Siamab Therapeutics, Inc. Composés interagissant avec le glycane et procédés d'utilisation
TW201622743A (zh) 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Carbosynth catalog page 71 (retrieved from http://www.carbosynth.com/Carbosynth/Catalogs.nsf/0/0560905FA1C2F42C80257E29004F2476/$FILE/Carbosynth_Oligosaccharide_Catalogue.pdf on 5/4/17, 1 page) *
Glycobricks (retrieved from https://acs.expoplanner.com/files/acsspring13/ExhibFiles/1046_3706_Elicityl-Oligotech-GlycoBricks.pdf on 5/3/17, 2 pages) *
Home Vet (retrieved from http://www.homevet.com/pet-care-library/item/382-what-are-the-signs-of-cancer-in-pets on 6/30/15, 3 pages) *
Kaldas Center (retrieved from http://kaldascenter.com/media/Kaldas-Center-Breast-Cancer.pdf on 6/30/15, 1 page) *
UICC (retrieved from http://www.uicc.org/programmes/childhood-cancer on 6/30/15, 1 page) *
Word Press (retrieved from https://chewychunks.wordpress.com/2015/01/30/why-two-thirds-of-cancer-cases-are-not-preventable/ on 6/30/15, 4 pages) *

Also Published As

Publication number Publication date
CN106456766B (zh) 2020-03-10
TWI681972B (zh) 2020-01-11
TW201623336A (zh) 2016-07-01
CN106456766A (zh) 2017-02-22
EP3119432B1 (fr) 2020-01-08
CA2943333A1 (fr) 2015-09-24
CN107073088A (zh) 2017-08-18
WO2015143123A2 (fr) 2015-09-24
KR20170003912A (ko) 2017-01-10
US20170107297A1 (en) 2017-04-20
AU2015231256A1 (en) 2016-09-22
US9828436B2 (en) 2017-11-28
MX2016012124A (es) 2017-04-06
JP2017518958A (ja) 2017-07-13
WO2015143123A3 (fr) 2015-11-26
IL247659A0 (en) 2016-11-30
EP3119432A4 (fr) 2017-09-13
EP3119424A4 (fr) 2017-09-13
EP3119424A1 (fr) 2017-01-25
WO2015143126A1 (fr) 2015-09-24
EP3119432A2 (fr) 2017-01-25
CA2943334A1 (fr) 2015-09-24
US20180371103A1 (en) 2018-12-27
US9951143B2 (en) 2018-04-24
US20170362337A1 (en) 2017-12-21
TW201622743A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
WO2015143126A1 (fr) Glycopeptides immunogènes, composition comprenant les glycopeptides et leur utilisation
Song et al. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response
US12280109B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
EP2467155A1 (fr) Vaccin multi-épitopique pour les cancers associés à la her2/neu
Li et al. Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy
US20180264093A1 (en) Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
US12311019B2 (en) Vaccine composition and uses thereof
US10532090B2 (en) Vaccine composition and uses thereof
Franco Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions
WO2021076897A1 (fr) Compositions et procédés de production de réponses immunitaires améliorées et production rapide d'anticorps
EA042396B1 (ru) Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах
HK1248536B (en) A vaccine composition and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANG, CHIH-LONG;WU, CHAO-CHIH;REEL/FRAME:040638/0376

Effective date: 20150731

AS Assignment

Owner name: DCB-USA, LLC, DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION;REEL/FRAME:040668/0215

Effective date: 20150922

Owner name: MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DCB-USA, LLC;MACKAY MEDICAL FOUNDATION THE PRESBYTERIAN CHURCH IN TAIWAN MACKAY MEMORIAL HOSPITAL;SIGNING DATES FROM 20160805 TO 20160810;REEL/FRAME:040668/0362

Owner name: MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH AND MACKAY MEMORIAL SOCIAL WORK FOUNDATION;REEL/FRAME:040668/0215

Effective date: 20150922

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION